SCHEMBL23578378

SCHEMBL23578378

COC(=O)c1cc2c(cc1Cl)C(C)(C(=O)OC)C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SERPINH1 P50454 1/20 0.34
ABL1 P00519 1/20 0.33
PDK2 Q15119 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
NR4A2 P43354 4/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183715 0.85 PGR (0.41) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL23590693 0.85 PGR (0.41) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL23590516 0.80 IP6K1 (0.45) MEN1KMT2AGHSR
SCHEMBL23590572 0.77 KMT2A (0.37) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL26123294 0.77 LCK (0.43) MAPTALDH1A1HPGDHSD17B10LMNA
SCHEMBL23577619 0.76 ATR (0.37) ALDH1A1HPGDGAAKDM4EBRD4
SCHEMBL9832724 0.76 KDM4E (0.36) MAPTALDH1A1HPGDHSD17B10GAA
SCHEMBL30623140 0.74 MAPT (0.41) MEN1KMT2AMAPTALDH1A1NPSR1
SCHEMBL30035074 0.74 MEN1 (0.38) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL23590971 0.74 MEN1 (0.38) MEN1KMT2AMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 CN disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 US disclosed
CN-115605476-A Substituted tricyclic compounds 鲁宾有限公司(IN) 2023-01-13 CN disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 WO disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 MEN1 44/4885KMT2A 4266/4885MAPT 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.